What is the 13F Pro Quality Score for FBIO?

13F Pro ranks Fortress Biotech, Inc. (FBIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FBIO's current score at https://13fpro.ai/company/FBIO (free sign-up required for the full ranking).

Where does 13F Pro source FBIO data?

All Fortress Biotech, Inc. fundamentals and ownership data come directly from SEC EDGAR. Fortress Biotech, Inc. files with the SEC under CIK 1429260. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FBIO in?

Fortress Biotech, Inc. (FBIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives FBIO's revenue?

Per Fortress Biotech, Inc.'s latest 10-Q filed with the SEC on 2026-08-13, the biggest revenue drivers are: Product revenue, net (Journey) ($17.8M, +19% YoY); Other revenue ($879K, -37% YoY); Emrosi ($8.1M, vs $2.8M PY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/FBIO.

What are FBIO's largest expenses?

Fortress Biotech, Inc.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($20.8M, -46% YoY); Cost of goods sold ($6.1M, +24% YoY); Research and development ($805K, -90% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is FBIO research updated on 13F Pro?

FBIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Fortress Biotech, Inc.(FBIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1429260 FBIO stock profile & AI dashboard →

13F Pro Quality Score

59.1/100

Rank #954 of 2,960 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

10.0/100

Profitability

99.6/100

Balance Sheet

99.3/100

Earnings Quality

63.5/100

Free Cash Flow

99.5/100

Institutional Flow

84.4/100

Revenue Scale

11.5/100

Dilution Risk

4.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why FBIO Scores 59/100

exact factor attribution · 2026-09-11

FBIO's composite is driven by profitability and free cash flow, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+7.4 pts

100th pct

Free cash flow

+7.4 pts

100th pct

Capital efficiency

+4.9 pts

99th pct

Earnings growth

+2.3 pts

95th pct

Institutional flow

+1.7 pts

84th pct

Earnings quality

+1.4 pts

64th pct

Shareholder dilution

-2.3 pts

5th pct

Scale

-5.8 pts

12th pct

Revenue growth

-8.0 pts

10th pct

Latest change (2026-08-16): 59 → 42 · ↓ Free cash flow 97→7; ↓ earnings_quality 51→2; despite ↑ Revenue growth 36→63

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in FBIO

Events flagged as statistical outliers against FBIO's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-16
FBIO quality score dropped 17 points (59→42) on a new filing
View source filing →

FBIO Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Fortress Biotech, Inc. (FBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FBIO at 59.1/100 on a 32-signal composite quality model, placing it at rank #954 of 2,960 stocks — the top half of the AI-ranked universe. FBIO scores in the top quartile across profitability (99.6), free cash flow (99.5), balance sheet strength (99.3). Areas of concern include revenue growth (10.0) and revenue scale (11.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Fortress Biotech, Inc. reports quarterly revenue of $18.7M, net income of $-468.0K, an operating margin of -53.5%. Top institutional holders of FBIO by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Opaleye Management, MACKENZIE FINANCIAL, based on the most recent SEC filings. FBIO trades on the Nasdaq exchange and files with the SEC under CIK 1429260. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fortress Biotech, Inc. directly from SEC EDGAR. Fortress Biotech, Inc.'s 13F Pro composite quality score has ranged between 9 and 69 since 2021, currently 59.1 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

What's Driving FBIO's Business? Latest 10-Q Breakdown

✓ 30/30 datapoints verified

AI-extracted from Fortress Biotech, Inc.'s 10-Q filed 2026-08-13 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net revenue rose 14% YoY to $18.7M on Emrosi's ramp, while the quarter's bottom line was lifted by a $10.7M non-cash gain on Urica's Crystalys equity stake following Cyprium's $205M PRV sale earlier in the year.

Biggest Revenue Drivers

Product revenue, net (Journey)$17.8M+19% YoY

Driven by Emrosi sales of $8.1M vs $2.8M a year ago, partly offset by lower Qbrexza and legacy product sales

Other revenue$879K-37% YoY

Includes $0.7M from Journey's Amzeeq supply/royalties to Cutia and $0.2M in Cyprium ZYCUBO royalties; prior-year quarter included Avenue's AJ201 termination payment

Biggest Revenue Drivers

Total revenue: $18.7M+14% YoY

Product revenue, net (Journey)$17.8M+19% YoY

Driven by Emrosi sales of $8.1M vs $2.8M a year ago, partly offset by lower Qbrexza and legacy product sales

Within Product revenue, net (Journey)

Emrosi$8.1Mvs $2.8M PY

Rosacea product launched March 2025; ~85% of US commercial lives now have access

Qbrexza$5.1M-26% YoY

Decrease attributed to coverage mix

Accutane$3.4M

Roughly flat YoY; faces generic competition

Other revenue$879K-37% YoY

Includes $0.7M from Journey's Amzeeq supply/royalties to Cutia and $0.2M in Cyprium ZYCUBO royalties; prior-year quarter included Avenue's AJ201 termination payment

Largest Expense Items

Selling, general and administrative$20.8M-46% YoY

Decline driven by deconsolidation of Checkpoint ($19.9M reduction), partly offset by higher Cyprium personnel/professional fees at Fortress

Cost of goods sold$6.1M+24% YoY

Increase driven by Amzeeq supply to Cutia and higher royalty expense on Emrosi net revenue growth

Research and development$805K-90% YoY

Prior year included $7.0M of Checkpoint R&D, which was deconsolidated in May 2025

Amortization of acquired intangible assets$969K-9% YoY

Eurax amortization began in Q1 2026, offset by completion of Accutane intangible amortization

Margins: The filing does not discuss gross or operating margin trends directly, but operating loss narrowed to $10.0M from $36.5M YoY, primarily due to the Checkpoint deconsolidation removing $26.9M of Checkpoint operating expenses from the comparison.

Watch Items from the Filing

Journey filed suit against Lupin in February 2026 after Lupin sought FDA approval for a generic Emrosi via ANDA, alleging Journey's patents (expiring January 2039) are invalid; the filing triggers a stay of Lupin's ANDA approval for up to 30 months.
Company had total undeclared Series A Preferred dividends of ~$16.0 million as of June 30, 2026, and remains ineligible to use Form S-3 shelf registrations until dividends are paid current.
Five of Journey's nine marketed products (Accutane, Targadox, Exelderm, Eurax, Luxamend) lack patent protection and face generic competition; Qbrexza revenue already declined 26% YoY partly on coverage mix.
Cyprium declared a ~$118.6M dividend in July 2026 (subsequent event), of which ~$95.4M is payable to Fortress, following the $205M PRV sale that closed in March 2026 — a major one-time cash infusion.
Mustang's net assets fell below $20 million in June 2026, triggering its election to delay a deferred payment obligation to uBriGene, signaling liquidity strain at that subsidiary.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$18.7M

Net Income

Q2 2026

$-468.0K

Operating Margin

Q2 2026

-53.5%

ROIC

Q2 2026

-20.1%

D/E Ratio

Q2 2026

0.21

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+9.7% YoY

$63.3MFY 2025

FY22 $75.7MFY23 $84.5MFY24 $57.7MFY25 $63.3M

Net Income

+114.8% YoY

$6.8MFY 2025

FY22 $-86.6MFY23 $-60.6MFY24 $-46.0MFY25 $6.8M

Operating Income

+36.4% YoY

$-70.2MFY 2025

FY22 $-203.6MFY23 $-142.3MFY24 $-110.4MFY25 $-70.2M

EPS (Diluted)

+97.4% YoY

$-0.07FY 2025

FY22 $-15.97FY23 $-8.47FY24 $-2.69FY25 $-0.07

Total Assets

+28.7% YoY

$185.5MFY 2025

FY22 $294.3MFY23 $167.5MFY24 $144.2MFY25 $185.5M

Total Debt

-6.0% YoY

$54.5MFY 2025

FY22 $91.7MFY23 $60.9MFY24 $58.0MFY25 $54.5M

Op. Cash Flow

+18.0% YoY

$-65.8MFY 2025

FY22 $-179.4MFY23 $-128.2MFY24 $-80.2MFY25 $-65.8M

Free Cash Flow

—FY 2025

FY22 $-182.1MFY23 $-128.3MFY24 $-80.2MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$63.3M +9.7%	$57.7M -31.8%	$84.5M +11.6%	$75.7M +10.1%	$68.8M +50.9%	$45.6M
Net Income	$6.8M +114.8%	$-46.0M +24.1%	$-60.6M +30.0%	$-86.6M -33.8%	$-64.7M -39.1%	$-46.5M
Operating Income	$-70.2M +36.4%	$-110.4M +22.5%	$-142.3M +30.1%	$-203.6M -8.0%	$-188.5M -100.0%	$-94.3M
EPS (Diluted)	$-0.07 +97.4%	$-2.69 +68.2%	$-8.47 +47.0%	$-15.97 -1921.5%	$-0.79	—
Total Assets	$185.5M +28.7%	$144.2M -13.9%	$167.5M -43.1%	$294.3M -25.8%	$396.5M +18.9%	$333.4M
Total Debt	$54.5M -6.0%	$58.0M -4.8%	$60.9M -33.7%	$91.7M +113.6%	$42.9M -16.9%	$51.7M
Operating Cash Flow	$-65.8M +18.0%	$-80.2M +37.5%	$-128.2M +28.5%	$-179.4M -53.9%	$-116.5M -39.3%	$-83.7M
Free Cash Flow	—	$-80.2M +37.5%	$-128.3M +29.6%	$-182.1M -50.4%	$-121.1M -41.5%	$-85.6M

Get alerted when FBIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Fortress Biotech, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FBIO

VANGUARD CAPITAL MANAGEMENT LLC
$3.2M1,037,203 sh
Opaleye Management Inc.
$2.7M890,000 sh
MACKENZIE FINANCIAL CORP
$1.7M555,676 sh
GSA CAPITAL PARTNERS LLP
$1.4M458,472 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.1M356,000 sh
SHIKIAR ASSET MANAGEMENT INC
$935.0K305,469 sh
GEODE CAPITAL MANAGEMENT, LLC
$919.9K300,521 sh
BlackRock, Inc.
$687.8K224,782 sh
TWO SIGMA INVESTMENTS, LP
$654.2K213,786 sh
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$542.7K177,368 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$3.2M	1,037,203
Opaleye Management Inc.	$2.7M	890,000
MACKENZIE FINANCIAL CORP	$1.7M	555,676
GSA CAPITAL PARTNERS LLP	$1.4M	458,472
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$1.1M	356,000
SHIKIAR ASSET MANAGEMENT INC	$935.0K	305,469
GEODE CAPITAL MANAGEMENT, LLC	$919.9K	300,521
BlackRock, Inc.	$687.8K	224,782
TWO SIGMA INVESTMENTS, LP	$654.2K	213,786
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$542.7K	177,368

Companies Similar to FBIO

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ETON

Eton Pharmaceuticals, Inc.

AI score

Similar quality profile · 2 shared holders

Opaleye Management Inc.Sheets Smith Investment Management

XOMA

XOMA Royalty Corp

AI score

Similar quality profile · 1 shared holders

Opaleye Management Inc.

LQDA

Liquidia Corp

AI score

Similar quality profile · 2 shared holders

Opaleye Management Inc.Integrated Quantitative Investments LLC

AUPH

Aurinia Pharmaceuticals Inc.

AI score

Similar quality profile

SNWV

SANUWAVE Health, Inc.

AI score

Similar quality profile · 1 shared holders

Opaleye Management Inc.

IRMD

IRADIMED CORP

AI score

Similar quality profile

ZVRA

ZEVRA THERAPEUTICS, INC.

AI score

Similar quality profile

SPRO

Spero Therapeutics, Inc.

AI score

Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FBIO on your watchlist

Track score changes the day Fortress Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FBIO a good stock to buy?

13F Pro's AI-powered analysis of Fortress Biotech, Inc. (FBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FBIO are available on the FBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FBIO is classified as a small company.

Which hedge funds own FBIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Fortress Biotech, Inc.'s investment landscape.